Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

PURPOSE: Subcutaneous APF530 provides controlled sustained release of granisetron to prevent acute (0–24 h) and delayed (24–120 h) chemotherapy-induced nausea and vomiting (CINV). This randomized, double-blind phase 3 trial compared APF530 and palonosetron in preventing acute and delayed CINV after...

Descripción completa

Detalles Bibliográficos
Autores principales: Raftopoulos, Harry, Cooper, William, O’Boyle, Erin, Gabrail, Nashat, Boccia, Ralph, Gralla, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311069/
https://www.ncbi.nlm.nih.gov/pubmed/25179689
http://dx.doi.org/10.1007/s00520-014-2400-3

Ejemplares similares

Ejemplares similares